Synchronous bilateral breast cancer with heterogeneous hormone receptor status: a case report
Open Access
- 1 December 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2024 (12) , rjae786
Abstract
The expression of estrogen, progesterone, and HER2 receptors in breast cancer cells helps guide treatment and predict outcomes. When the status of these receptors is heterogeneous, it makes treatment planning more complex. We present the case of a 72-year-old woman with bilateral breast cancer with heterogenous receptor status and subsequent challenges in management.Keywords
This publication has 18 references indexed in Scilit:
- Neoadjuvant or adjuvant chemotherapy in early breast cancer?Expert Opinion on Pharmacotherapy, 2020
- Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancerBiomedical Papers, 2019
- Progress in the clinical detection of heterogeneity in breast cancerCancer Medicine, 2016
- Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancersThe Breast, 2015
- Prognosis of synchronous bilateral breast cancer: a review and meta-analysis of observational studiesBreast Cancer Research and Treatment, 2014
- Neoadjuvant Therapy in the Treatment of Breast CancerSurgical Oncology Clinics of North America, 2014
- Neoadjuvant chemotherapy in breast cancerCurrent Opinion in Supportive & Palliative Care, 2014
- Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristicsBreast Cancer Research and Treatment, 2010
- Preoperative chemotherapy for women with operable breast cancerCochrane Database of Systematic Reviews, 2007
- Bilateral synchronous breast cancer: Mode of detection and comparison of histologic features between the 2 breastsSurgery, 2000